title: [Our experience of eribulin treatment in advanced breast cancer].
abstract: The clinical outcomes, including adverse events, in 40 advanced breast cancer patients treated with eribulin were analyzed to confirm the effectiveness and safety of this treatment. The objective response rate (ORR) in patients was 35.0%. The median overall survival and time to treatment failure (TTF) in these patients was 479 and 63 days, respectively. Cases wherein eribulin was used as early-line treatment experienced significantly longer TTF compared to the cases wherein eribulin was used as late-line treatment; however, there was no difference in this value according to the breast cancer subtype. Moreover, subtype analysis revealed no significant difference in adverse events. We observed no difference in the benefit or tolerability of eribulin treatment among different breast cancer subtypes. However, our results suggest that a significant therapeutic effect can be expected when using eribulin as early-line treatment.
authors.affiliation: Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Kashiwagi
authors.forename: Sae
authors.initials: S
authors.lastname: Ishihara
authors.forename: Mariko
authors.initials: M
authors.lastname: Ishii
authors.forename: Yuka
authors.initials: Y
authors.lastname: Asano
authors.forename: Mao
authors.initials: M
authors.lastname: Watanabe
authors.forename: Tamami
authors.initials: T
authors.lastname: Morisaki
authors.forename: Naoki
authors.initials: N
authors.lastname: Aomatsu
authors.forename: Satoru
authors.initials: S
authors.lastname: Noda
authors.forename: Hidemi
authors.initials: H
authors.lastname: Kawajiri
authors.forename: Taeko
authors.initials: T
authors.lastname: Nakano
authors.forename: Noriko
authors.initials: N
authors.lastname: Kawakami
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Mitsukawa
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takashima
authors.forename: Naoyoshi
authors.initials: N
authors.lastname: Onoda
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Kosei
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005663:Furans / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome; D000095662:Polyether Polyketides
chemical_list: D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides